1 / 31

Bladder cancer

Bladder cancer. Urothelial tumors. -90% in bladder -8% renal pelvis -2% ureters and urethra. Histology of bladder cancer. Urothelial-more than 90% of bladder cancer Squamous cell carcinoma-5% of bladder cancer

scott-massey
Télécharger la présentation

Bladder cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bladder cancer

  2. Urothelial tumors -90% in bladder -8% renal pelvis -2% ureters and urethra

  3. Histology of bladder cancer • Urothelial-more than 90% of bladder cancer • Squamous cell carcinoma-5% of bladder cancer -worldwide, this is the most common form, accounting for 75% of bladder cancer in underdeveloped nations. -In the industrialized countries SCC is associated with persistent inflammation from long-term indwelling Foley catheters and bladder stones. -In underdeveloped nations, SCC is associated with bladder infestation by Schistosoma haematobium.

  4. Etiology-Urothelial tumors I. Environmental factors-implicated in more than 80% of bladder cancer -50% caused by tobacco use (increases the risk 3x) -aromatic amines, aniline dyes, nitrites and nitrates -industrial contact to chemicals, plastics, coal, tar and asphalt -cyclophosphamide II. Genetic factors

  5. Etiology-SCC • Schistosoma haematobium • Parasitic trematode=flatworm • found in large parts of Africa, parts of the Arabia, the Middle East, Iran, Madagascar and Mauritius. • Infection occurs through contact with fresh water that contains infective cercariae released from an intermediate host snail. Male worms are longer and thicker. They possess a structure known as a gynecophoral canal running the length of the body in which the female remains during much of the life cycle. The thinner female separates from her mate to migrate to the venules bordering the intestine or bladder in order to deposit eggs.

  6. Etiology-SCC • Irritative risk factors: • long-term indwelling Foley catheters • bladder stones

  7. Symptoms • 80-90% of patients with bladder cancer present with painless gross hematuria Consider all patients with gross hematuria to have bladder cancer until proven otherwise. Suspect bladder cancer if any patient presents with unexplained microscopic hematuria. • 20-30% present irritative bladder symptoms such as dysuria, urgency or frequency of urination that are related to • more advanced muscle-invasive disease or • CIS • Patients with advanced disease can present with pelvic or bony pain, lower-extremity edema from iliac vessel compression or flank pain from ureteral obstruction

  8. Diagnosis • Cystoscopy with TUR-V (transurethral resection) • Clinical examination for inguinal lymph nodes • CT/MRI/PET-CT of pelvis and abdomen • Chest radiography

  9. TUR-V (click on the video)

  10. Treatment • Non-muscle invasive bladder cancer: TUR-V +/- intravesical chemotherapy instillation or intravesical BCG (Bacillus Calmette-Guerin)

  11. Treatment • Muscle invasive bladder cancer: • Bladder conserving therapy: maximal TUR-V or segmental cystectomy followed by chemoradiation • Cystectomy plus pelvic lymphadenectomy

  12. Questions • What are the two main types of bladder cancer and what risk factors do they have? • What is the treatment for non-muscle invading bladder cancer? • What are the treatment choices for muscle-invading bladder cancer?

  13. Prostate cancer(prostate adenocarcinoma)

  14. Epidemiology USA: surpassed lung cancer in known incidence around 1990 due to PSA screening One project that analyzed autopsy studies from around the world came to the following conclusion regarding the actual rate of prostate cancer in men of different ages: 20 to 30 years, 2% to 8% 31 to 40 years: 9% to 31% 41 to 50 years: 3% to 43% 51 to 60 years: 5% to 46% 61 to 70 years: 14% to 70% 71 to 80 years: 31% to 83% 81 to 90 years: 40% to 73%

  15. Risk factors • Genetic • e.g. BRCA1/2 mutations • black race II. Environmental -high fat and red meat plus low fruits + vegetables diet -cause not exactly known

  16. Extension Local: through the prostatic capsule, through the seminal vesicles Regional lymph nodes: lymph nodes from the true pelvis Metastases: most frequent-bone

  17. Symptoms Bladder Outlet Obstruction (BOO): weak urinary stream, frequent (nocturnal) and voiding incomplete emptying of the bladder The two most probable causes BOO are a weakly contracting bladder muscle or Benign Prostatic Hyperplasia (BPH) followed by prostate cancer More advanced stages: -lumbar pain due to para-aortic metastases/bone meta -other bone pain

  18. Diagnosis • Digital rectal examination (prostatic nodule) • PSA • US guided prostate biopsy

  19. PSA is not a perfect test:-men with a PSA level below the age-specific limit of normal can have cancer -PSA is not cancer-specific and is produced by both cancerous and non-cancerous prostate cells [increased PSA can occur is benign prostatic hyperplasia (BPH, i.e. prostate enlargement) or prostatitis (infection of the prostate]

  20. US guided prostate biopsy

  21. Diagnosis (2) • US guided prostate biopsy • Examinations for extension: • -rectal US • -pelvine MRI • -scintigraphy with anti-PSMA (prostate specific membrane antigen) antibodies (“prostascint”) • -bone scintigraphy

  22. Prostascint Abnormal ProstaScint accumulation is demonstrated in the seminal vesicles (red arrows on image A) and right pelvic lymph nodes (yellow arrow on image B).

  23. Scintigraphy with PET and Technetium

  24. Treatment • Life expectancy is important in the decision to treat or not a certain patient

  25. Treatment • Watchful waiting -for patients with a life expectancy of less than 5 years because of comorbidities plus have to be asymptomatic 2. (Nerve sparing) radical prostatectomy plus pelvic lymphadenectomy -side effects: 40-90% impotence, 10% incontinence

  26. Treatment 3. Prostate brachytherapy-mainly for cancer localized to the prostate • LDR (low dose rate; seed implant) • HDR (high dose rate; treatment through catheters)

  27. Treatment 4. External beam radiotherapy -for cancer limited to the prostate -for cancer spread to the seminal vesicles and/or lymph nodes

  28. Treatment 5. Hormonal treatment -associated to surgery/radiotherapy -alone in metastatic disease -consists of androgen deprivation therapy through LHRH agonist or orchiectomy 6. Chemotherapy -in metastatic disease

  29. Screening After discussing potential benefits and harms of screening • From 50 yrs in normal risk men with DRE and PSA • From 40 yrs in men with increased risk (first degree relative with prostate cancer, black race)

  30. Questions • What are the treatment modalities in prostate cancer? • How is screening done in prostate cancer?

More Related